New combo therapy aims to stop breast cancer brain metastases

NCT ID NCT04923542

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Nov 15, 2025 · Last updated Jun 16, 2026 · Updated 33 times

Summary

This study is for people with a specific type of breast cancer (HR+/HER2-) that has spread to the brain. It tests whether adding a targeted drug called abemaciclib to precise radiation therapy can better control the brain tumors. About 31 participants will receive both treatments, and researchers will track how long the brain tumors stay under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Moffitt Cancer Center
ACTIVE_NOT_RECRUITING

Tampa, Florida, 33612, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact

Conditions

The condition(s) this trial relates to.

brain cancer hormone receptor-positive breast cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES HR+ METASTATIC BREAST CANCER HR+ METASTATIC BREAST CANCER